Kuboi Takuro, Tajika Tsuyoshi, Endo Fumitaka, Goto Wataru, Nakajima Ichiro, Hasegawa Satoshi, Nakajima Daisuke, Hasokawa Takafumi, Chikuda Hirotaka
Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.
Department of Rehabilitation, Gunma University Graduate School of Health Sciences, Maebashi, Japan.
Prog Rehabil Med. 2021 May 26;6:20210023. doi: 10.2490/prm.20210023. eCollection 2021.
This study was conducted to investigate the changes in clinical and psychosocial outcomes in patients with Dupuytren's disease after initial treatment with collagenase (CCH) injection.
This study involved 14 patients with Dupuytren's disease who underwent treatment with CCH injection. The range of motion of each phalangeal joint was measured before treatment and at 6 months posttreatment. The following assessments were also carried out pre- and posttreatment: the Geriatric Depression Scale Short - Japanese version (GDS-J) to evaluate depressive status, Hand 10 to assess hand health status, and EuroQol-5-dimension-3-level Japanese version to evaluate health-related quality of life.
Significant improvements were found in metacarpophalangeal joint extension and proximal interphalangeal joint extension. Significant differences were also found between values before the initiation of CCH injection and those at 6 months posttreatment for the EuroQol index score and the EuroQol Visual Analog Scale (VAS). Significant positive correlations were found between the pre- to posttreatment change in GDS-J scores and for the change in Hand 10 scores. Moreover, a significant negative correlation was found between the change in GDS-J scores and change in EuroQol index scores/EuroQol VAS scores before and at 6 months after CCH injection.
For patients with Dupuytren's disease, CCH therapy directly improved the health-related quality of life. The degree of improvement of depressive status was associated with the degree of improvement of hand health status and health-related quality of life.
本研究旨在调查接受胶原酶（CCH）注射初始治疗后的掌腱膜挛缩症患者临床和心理社会结局的变化。
本研究纳入了14例接受CCH注射治疗的掌腱膜挛缩症患者。在治疗前和治疗后6个月测量每个指关节的活动范围。在治疗前和治疗后还进行了以下评估：采用老年抑郁量表简版日语版（GDS-J）评估抑郁状态，采用手部10项评估手部健康状况，采用欧洲五维度健康量表3级日语版评估健康相关生活质量。
掌指关节伸展和近端指间关节伸展有显著改善。CCH注射开始前和治疗后6个月时的欧洲五维度健康量表指数评分和欧洲五维度健康量表视觉模拟量表（VAS）值之间也存在显著差异。GDS-J评分的治疗前后变化与手部10项评分的变化之间存在显著正相关。此外，CCH注射前和注射后6个月时，GDS-J评分的变化与欧洲五维度健康量表指数评分/欧洲五维度健康量表VAS评分的变化之间存在显著负相关。
对于掌腱膜挛缩症患者，CCH治疗直接改善了健康相关生活质量。抑郁状态的改善程度与手部健康状况和健康相关生活质量的改善程度相关。
